Inhibition of Tissue-Type Plasminogen Activator in Plasma of Women Using Oral Contraceptives and in Normal Women During a Menstrual Cycle

Summary

Tissue-type plasminogen activator (t-PA) inhibition in plasma was assessed in 15 normal women and in 10 women using oral contraceptives (OC) containing 30 μg ethinyl oestradiol and 150 μg levo-norgestrel. The levels of t-PA inhibition were significantly lower in the OC group with marked fluctuations related to the hormone cycle. Normal women had only minor fluctuations.

Keywords

Fibrinolysis - Tissue-type plasminogen activator - Tissue-type plasminogen activator inhibition - Menstrual cycle - Oral contraceptives

• References

• 1 Verheijen JH, Rijken DC, Brommer EJ P, Chang GT G. Measurement of tissue-type plasminogen activator activity, antigen, and inhibition in plasma. In: Clinical aspects of fibrinolysis and thrombolysis Jespersen J, Kluft C, Korsgaard O. (eds.) South Jutland University Press; Esbjerg: 1983: 121-131
• 2 Chmielewska J, Råndy M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436
• 3 Kruithof EK O, Ransijn A, Bachmann F. Inhibition of tissue plasminogen activator by human plasma. In: Progress in fibrinolysis Davidson JF, Bachmann F, Bouvier CA, Kruithof EK O. (eds.) Churchill Livingstone; Edinburgh: 1983: 365-369
• 4 Kruithof EK O, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
• 5 Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-1472
• 6 Verheijen JH, Chang GT G, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
• 7 Philips M, Thorsen S. Binding of plasminogen. activator (PA) to a component (x) of endothelial cells (EC) may explain the 95.000 M,. PA in human plasma. Thromb Haemostas 1983; 50: 193
• 8 Sprengers ED, Princen HM G, Kooistra T, van Hinsbergh VW M. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med 1985; 105: 751-758
• 9 Kluft C, Verheijen JH, Jie AF H, Rijken DC, Preston FE, Sue-Ling HM, Jespersen J, Aasen AO. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45: 605-610
• 10 Verheijen JH, Rijken DC, Chang GT G, Preston FE, Kluft C. Modulation of rapid plasminogen activator inhibitor in plasma by stanozolol. Thromb Haemostas 1984; 51: 396-397
• 11 Jespersen J. A study of the antithrombotic potential in women on oral contraceptives low in oestrogen. Its relation to the present knowledge of the mechanism and the pathophysiological aspects of the thrombo-haemorrhagic balance In: Clinical aspects of fibrinolysis and thrombolysis. Jespersen J, Kluft C, Korsgaard O. (eds.) South Jutland University Press; Esbjerg: 1983: 399-419
• 12 Jespersen J, Kluft C. Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen. Levels of extrinsic, and intrinsic plasminogen activators, prekallikrein, factor XII, and Cl-inactivator. Thromb Haemostas 1985; 54: 454-459
• 13 Jespersen J. A sequential study of plasma euglobulin fibrinolytic activity during the normal menstrual cycle and in women on oral contraceptives low in estrogen. Gynecol Obstet Invest 1983; 15: 266-274
• 14 Jespersen J, Knudsen LH, Sidelmann J. The use of evacuated glass tubes for collection of blood samples for fibrinolytic assays. Thromb Res 1982; 25: 173-176
• 15 Hønger PE, Rossing N. Albumin metabolism and oral contraception. Clin Sci 1969; 36: 41-45
• 16 Wiman B, Csemiczky G, Marsk L, Robbe H. The fast inhibitor of tissue plasminogen activator in plasma during pregnancy. Thromb Haemostas 1984; 52: 124-126